Selected Publications
2024
Huang Y, Rauh-Hain JA, McCoy TH, Hou JY, Hillyer G, Ferris JS, Hershman D, Wright JD, Melamed A. Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning. Gynecol Oncol. 2024;186:9-
Jorgensen KA, Agusti N, Wu CF, Kanbergs A, Pareja R, Ramirez PT, Rauh-Hain JA, Melamed A. Fertility-sparing surgery vs standard surgery for early-stage cervical cancer: difference in 5-year life expectancy by tumor size. Am J Obstet Gynecol. 2024:S0002-9378(24)00084-X.
Freret TS, Cohen JL, Gyamfi-Bannerman C, Kaimal AJ, Lorch SA, Wright JD, Melamed A*, Clapp MA*. Regional Variation in Antenatal Late Preterm Steroid Use Following the ALPS Trial. JAMA Netw Open. 2024;7:e2350830. (co-senior author)
Melamed A, Eisenhauer EL. Minimally invasive interval cytoreductive surgery for advanced ovarian cancer. J Surg Oncol. 2024 ;129(1):126-127.
2023
Abel MK, Myers EL, Minkin E, Tahir P, Haynes AB, Wright JD, Rauh-Hain JA, Melamed A. Cancer-directed surgery in patients with metastatic cancer: A systematic review and meta-analysis of randomized evidence. Cancer Med. 2023;12(13):14072-14083
Silberman JN, Bercow AS, Gockley AA, Eisenhauer EL, Sisodia R, Randall T, Del Carmen MG, Goodman A, Castro CM, Melamed A*, Bregar AJ. Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States. Gynecol Oncol. 2023;175:60-65. (co-senior author)
Melamed A, Lin YL, Hassan AM, Rauh-Hain JA, Herring B, Keating NL, Offodile AC 2nd. Trends in Episode-of-Care Spending for Cancer-Directed Surgery Among US Medicare Beneficiaries From 2011 to 2019. JAMA Surg. 2023;158(2):216-218.
2022
Nitecki R, Melamed A. Extra cycles of neoadjuvant chemotherapy before interval surgery for ovarian cancer: the more the merrier or too much of a good thing? Int J Gynecol Cancer. 2022;32:975–976.
Clapp MA*, Melamed A*, Freret TS, James KE, Gyamfi-Bannerman C, Kaimal AJ. US Incidence of Late-Preterm Steroid Use and Associated Neonatal Respiratory Morbidity After Publication of the Antenatal Late Preterm Steroids Trial, 2015-2017. JAMA Netw Open. 2022;5(5):e2212702. (*co-first authors)
Cham S, Li A, Rauh-Hain JA, Tergas AI, Hershman DL, Wright JD, Melamed A. Association Between Neighborhood Socioeconomic Inequality and Cervical Cancer Incidence Rates in New York City. JAMA Oncol. 2022;8(1):159-161.
2021
Melamed A, Rauh-Hain JA, Gockley AA, Nitecki R, Ramirez PT, Hershman DL, Keating N, Wright JD. Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer. JAMA Oncol. 2021 Dec 1;7(12):1782-1790.
Nitecki R*, Melamed A*, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol Oncol. 2021 161(3):653-659. (*co-first authors)
Knisely A, Gamble CR, St Clair CM, Hou JY, Khoury-Collado F, Gockley AA, Wright JD, Melamed A. The Role of Minimally Invasive Surgery in the Care of Women with Ovarian Cancer: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2021;28(3):537-543.
2020
Knisely AT, St Clair CM, Hou JY, Collado FK, Hershman DL, Wright JD, Melamed A. Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016. JAMA Netw Open. 2020;3(9):e2017517.
Emeruwa UN, Ona S, Shaman JL, Turitz A, Wright JD, Gyamfi-Bannerman C, Melamed A. Associations Between Built Environment, Neighborhood Socioeconomic Status, and SARS-CoV-2 Infection Among Pregnant Women in New York City. JAMA. 2020;324(4):390-392.
Nitecki R, Ramirez PT, Frumovitz M, Krause KJ, Tergas AI, Wright JD, Rauh-Hain JA, Melamed A. Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2020;6(7):1019-1027.
Melamed A, Ramirez PT. Changing treatment landscape for early cervical cancer: outcomes reported with minimally invasive surgery compared with an open approach. Curr Opin Obstet Gynecol. 2020;32(1):22-27.
Nitecki R, Melamed A. Time to accept a new old standard of care in cervical cancer. Int J Gynecol Cancer. 2020;30(9):1278-1279.
2019
Melamed A, Rauh-Hain JA, Ramirez PT. Minimally Invasive Radical Hysterectomy for Cervical Cancer: When Adoption of a Novel Treatment Precedes Prospective, Randomized Evidence. J Clin Oncol. 2019;37(33):3069-3074.
Melamed A, Bercow AS, Bunnell K, Rauh-Hain JA, Wright JD, Rice LW, Del Carmen MG. Age-Associated Risk of 90-Day Postoperative Mortality After Cytoreductive Surgery for Advanced Ovarian Cancer. JAMA Surg. 2019;154(7):669-671.
Moss HA, Melamed A, Wright JD. Measuring cause-and-effect relationships without randomized clinical trials: Quasi-experimental methods for gynecologic oncology research. Gynecol Oncol. 2019;152(3):533-539.
2018
Melamed A, Margul DJ, Chen L, Keating NL, Del Carmen MG, Yang J, Seagle BL, Alexander A, Barber EL, Rice LW, Wright JD, Kocherginsky M, Shahabi S, Rauh-Hain JA. Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. N Engl J Med. 2018;379(20):1905-1914
Melamed A, Fink G, Wright AA, Keating NL, Gockley AA, Del Carmen MG, Schorge JO, Rauh-Hain JA. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study. BMJ. 2018;360:j5463
Complete bibliography here.
